FIG 2.

Treatment of T-ALL IF. (A) Swimmer plot displaying postinduction treatment of patients with IF split by trial. Standard chemotherapy indicates standard trial treatment. Nelarabine indicates nelarabine given either alone or in combination with other agents. High-dose chemotherapy indicates other non–nelarabine-containing regimens, most commonly FLA-IDA. (B) Kaplan-Meier plot showing OS of patients treated with nelarabine versus those not treated with nelarabine. (C) Kaplan-Meier plot showing OS of patients who received SCT versus those who did not. The SCT group included 33 patients (one excluded as underwent SCT when not in remission). The no SCT group included all 31 patients who remitted and were alive and in remission on day 91 (the date of the earliest SCT). (D) Kaplan-Meier plot showing OS of patients with end-of-consolidation MRD more than 1% versus MRD < 1%. CR, complete remission; FLA-IDA, fludarabine, cytarabine, idarubicin chemotherapy; HSCT, hematopoietic stem-cell transplantation; IF, induction failure; MRD, minimal residual disease; OS, overall survival; SCT, stem-cell transplant; T-ALL, T-cell acute lymphoblastic leukemia.